Nicholas George Strong

Shell International Ltd. provides business support services. It engages in upstream and downstream oil and gas businesses in the United Kingdom and internationally. The company is headquartered in London, the United Kingdom.

Part of UniPhar Group Ltd., Cahill May Roberts Ltd. is a pharmaceutical product distributor. The company is based in Chapelizod, Ireland. Cahill May Roberts was acquired by UniPhar Group Ltd. from McKesson Europe AG on April 30, 2013 for $63.43 million.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Helix Health Group Ltd. provides practice management and pharmacy software services. The company was founded by Howard J. Beggs on November 10, 2006 and is headquartered in Dublin, Ireland.

The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing.